AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
Top Cited Papers
Open Access
- 19 October 2006
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (16) , 1672-1681
- https://doi.org/10.1056/nejmoa054626
Abstract
Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1–2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP. In phase 1, 24 patients who had received at least one treatment for ITP were assigned to escalating-dose cohorts of 4 patients each and given two identical doses of AMG 531 (0.2 to 10 μg per kilogram of body weight). In phase 2, 21 patients were randomly assigned to receive six weekly subcutaneous injections of AMG 531 (1, 3, or 6 μg per kilogram) or placebo. The primary objective was to assess the safety of AMG 531; the secondary objective was to evaluate platelet counts during and after treatment. No major adverse events that could be attributed directly to AMG 531 occurred during the treatment period; 4 of 41 patients had transient post-treatment worsening of thrombocytopenia. In phase 1, a platelet count that was within the targeted range (50,000 to 450,000 per cubic millimeter) and at least twice the baseline count was achieved in 4 of 12 patients given 3, 6, or 10 μg of AMG 531 per kilogram. Overall, a platelet count of at least 50,000 per cubic millimeter was achieved in 7 of 12 patients, including 3 with counts exceeding 450,000 per cubic millimeter. Increases in the platelet count were dose-dependent; mean peak counts were 163,000, 309,000, and 746,000 per cubic millimeter with 3, 6, and 10 μg of AMG 531 per kilogram, respectively. In phase 2, the targeted platelet range was achieved in 10 of 16 patients treated with 1 or 3 μg of AMG 531 per kilogram per week for 6 weeks. Mean peak counts were 135,000, 241,000, and 81,000 per cubic millimeter in the groups that received the 1-μg dose, the 3-μg dose, and placebo, respectively. AMG 531 caused no major adverse events and increased platelet counts in patients with ITP. (ClinicalTrials.gov number, NCT00111475.)Keywords
This publication has 37 references indexed in Scilit:
- How I treat idiopathic thrombocytopenic purpura (ITP)Blood, 2005
- Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodiesAmerican Journal of Hematology, 2004
- Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITPBlood, 2004
- Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpuraBlood, 2004
- Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancyBritish Journal of Haematology, 2003
- The role of transforming growth factor‐β in PEG‐rHuMGDF‐induced reversible myelofibrosis in ratsBritish Journal of Haematology, 1997
- Serum Thrombopoietin Level in Various Hematological DiseasesThe International Journal of Cell Cloning, 1996
- Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.Journal of Clinical Investigation, 1987
- Kinetics and sites of destruction of111indium-oxine-labeled platelets in idiopathic thrombocytopenic purpura: A quantitative studyAmerican Journal of Hematology, 1982
- Chronic Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 1981